To determine whether genetic variants in a pharmacokinetic gene (the number of CYP2C19 reduced function alleles [RFAs]), and in pharmacodynamic genes (HTR2A, SLC6A4, and GRIK4) influence sertraline tolerability and response in a cohort of pediatric patients with anxiety and depressive disorders.
Methods:
A retrospective analysis was performed using the electronic medical record data of 352 patients <19 years of age being treated for anxiety and/or depressive disorders with sertraline and who underwent routine clinical CYP2C19 genotyping. Additional genotyping and analysis of variants in HTR2A, SLC6A4, and GRIK4 were conducted for 249 patients. Multivariate regression models testing for associations with CYP2C19 were adjusted for concomitant use of interacting medications. Combinatorial classification and regression tree (CART) analyses containing all pharmacokinetic and pharmacodynamic genes and clinical factors were performed.
Results:
The maximum sertraline dose during the initial titration period of sertraline was inversely associated with the number of CYP2C19 RFAs and sertraline dose at 60 (p = 0.025) and 90 days (p = 0.025). HTR2A rs6313 was associated with sertraline dose (p = 0.011) and time to the average maximum sertraline dose (p = 0.039). Regarding efficacy, the number of CYP2C19 RFAs was not associated with the sertraline dose at the time of response (p = 0.22), whereas for the pharmacodynamic genes, only HTR2A rs6313 was associated with response dose (p = 0.022). An association was observed between predicted expression levels of SLC6A4 and the duration on sertraline (p = 0.025). Combinatorial CART and multivariate regression analyses implicated that pharmacodynamic genes and clinical factors influence the maximum sertraline dose and response dose. The total number of side effects was not associated with any of the variants tested.
Conclusion:
Both pharmacokinetic and pharmacodynamic factors, in addition to clinical and demographic components, influence sertraline dose, response, and tolerability, thereby necessitating further research to assess for the validity of these pharmacogenetic associations in children and adolescents.
Get full access to this article
View all access options for this article.
References
1.
AkpinarE, CeritC, TalasA, TuralU: Agomelatine versus sertraline: An observational, open-labeled and 12 weeks follow-up study on efficacy and tolerability. Clin Psychopharmacol Neurosci, 14:351–356, 2016.
2.
AldermanJ, WolkowR, FogelIM: Drug concentration monitoring with tolerability and efficacy assessments during open-label, long-term sertraline treatment of children and adolescents. J Child Adolesc Psychopharmacol, 16:117–129, 2006.
3.
AldrichSL, PoweleitE, ProwsCA, MartinLJ, StrawnJR, RamseyLB: Influence of CYP2C19 metabolizer status on escitalopram/citalopram tolerability and response in youth with anxiety and depressive disorders. Front Pharmacol, 10:99, 2019.
4.
AltarCA, CarhartJM, AllenJD, Hall-FlavinDK, DechairoBM, WinnerJG: Clinical validity: Combinatorial pharmacogenomics predicts antidepressant responses and healthcare utilizations better than single gene phenotypes. Pharmacogenomics J, 15:443–451, 2015.
5.
AltarCA, HornbergerJ, ShewadeA, CruzV, GarrisonJ, MrazekD: Clinical validity of cytochrome P450 metabolism and serotonin gene variants in psychiatric pharmacotherapy. Int Rev Psychiatry, 25:509–533, 2013.
6.
AmitaiM, KronenbergS, CarmelM, MichaelovskyE, FrischA, BrentD, ApterA, ChenA, WeizmanA, FennigS: Pharmacogenetics of citalopram-related side effects in children with depression and/or anxiety disorders. J Neural Transm (Vienna), 123:1347–1354, 2016.
7.
Beesdo-BaumK, KnappeS: Developmental epidemiology of anxiety disorders. Child Adolesc Psychiatr Clin N Am, 21:457–478, 2012.
8.
BogettoF, AlbertU, MainaG: Sertraline treatment of obsessive-compulsive disorder: Efficacy and tolerability of a rapid titration regimen. Eur Neuropsychopharmacol, 12:181–186, 2002.
9.
BousmanCA, MullerDJ: Pharmacogenetics in psychiatry: A companion, rather than competitor, to protocol-based care. JAMA Psychiatry, 75:1090, 2018.
10.
BreimanL, FriedmanJ, OlshenR, StoneC: Classification and Regression Trees. New York, Chapman and Hall, 1984
11.
BusnerJ, TargumSD: The clinical global impressions scale: Applying a research tool in clinical practice. Psychiatry (Edgmont), 4:28–37, 2007.
12.
CarlssonB, OlssonG, ReisM, WalinderJ, NordinC, LundmarkJ, ScordoMG, DahlML, BengtssonF, AhlnerJ: Enantioselective analysis of citalopram and metabolites in adolescents. Ther Drug Monit, 23:658–664, 2001.
13.
CaudleKE, DunnenbergerHM, FreimuthRR, PetersonJF, BurlisonJD, Whirl-CarrilloM, ScottSA, RehmHL, WilliamsMS, KleinTE, RellingMV, HoffmanJM: Standardizing terms for clinical pharmacogenetic test results: Consensus terms from the Clinical Pharmacogenetics Implementation Consortium (CPIC). Genet Med, 19:215–223, 2017.
14.
CiprianiA, ZhouX, Del GiovaneC, HetrickSE, QinB, WhittingtonC, CoghillD, ZhangY, HazellP, LeuchtS, CuijpersP, PuJ, CohenD, RavindranAV, LiuY, MichaelKD, YangL, LiuL, XieP: Comparative efficacy and tolerability of antidepressants for major depressive disorder in children and adolescents: A network meta-analysis. Lancet, 388:881–890, 2016.
15.
GassoP, BlazquezA, RodriguezN, BolocD, TorresT, MasS, LafuenteA, LazaroL: Further support for the involvement of genetic variants related to the serotonergic pathway in the antidepressant response in children and adolescents after a 12-month follow-up: Impact of the HTR2A rs7997012 polymorphism. J Child Adolesc Psychopharmacol [Epub ahead of print]; DOI: 10.1089/cap.2018.0004, 2018.
16.
GjestadC, WestinAA, SkogvollE, SpigsetO: Effect of proton pump inhibitors on the serum concentrations of the selective serotonin reuptake inhibitors citalopram, escitalopram, and sertraline. Ther Drug Monit, 37:90–97, 2015.
17.
GredenJF, ParikhSV, RothschildAJ, ThaseME, DunlopBW, DeBattistaC, ConwayCR, ForesterBP, MondimoreFM, SheltonRC, MacalusoM, LiJ, BrownK, GilbertA, BurnsL, JablonskiMR, DechairoB: Impact of pharmacogenomics on clinical outcomes in major depressive disorder in the GUIDED trial: A large, patient- and rater-blinded, randomized, controlled study. J Psychiatr Res, 111:59–67, 2019.
18.
GuyW: ECDEU Assessment Manual for Psychopharmacology. Rockville (Maryland), U.S. Department of Health, Education, and Welfare, Public Health Service, Alcohol, Drug Abuse, and Mental Health Administration, National Institute of Mental Health, Pscyhopharmacology Research Branch, Division of Extramural Research Programs, 1976.
19.
HicksJK, BishopJR, SangkuhlK, MullerDJ, JiY, LeckbandSG, LeederJS, GrahamRL, Chiulli DLA LL, SkaarTC, ScottSA, StinglJC, KleinTE, CaudleKE, GaedigkA: Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6 and CYP2C19 genotypes and dosing of selective serotonin reuptake inhibitors. Clin Pharmacol Ther, 98:127–134, 2015.
20.
HorstmannS, LucaeS, MenkeA, HenningsJM, IsingM, RoeskeD, Muller-MyhsokB, HolsboerF, BinderEB: Polymorphisms in GRIK4, HTR2A, and FKBP5 show interactive effects in predicting remission to antidepressant treatment. Neuropsychopharmacology, 35:727–740, 2010.
21.
HuXZ, LipskyRH, ZhuG, AkhtarLA, TaubmanJ, GreenbergBD, XuK, ArnoldPD, RichterMA, KennedyJL, MurphyDL, GoldmanD: Serotonin transporter promoter gain-of-function genotypes are linked to obsessive-compulsive disorder. Am J Hum Genet, 78:815–826, 2006.
22.
KatoM, NonenS, SerrettiA, TetsuoS, TakekitaY, AzumaJ, KinoshitaT: 5-HTTLPR rs25531A > G differentially influence paroxetine and fluvoxamine antidepressant efficacy: A randomized, controlled trial. J Clin Psychopharmacol, 33:131–132, 2013.
23.
KatoM, SerrettiA: Review and meta-analysis of antidepressant pharmacogenetic findings in major depressive disorder. Mol Psychiatry, 15:473–500, 2010.
24.
KawaguchiDM, GlattSJ: GRIK4 polymorphism and its association with antidepressant response in depressed patients: A meta-analysis. Pharmacogenomics, 15:1451–1459, 2014.
25.
KraftJB, SlagerSL, McGrathPJ, HamiltonSP: Sequence analysis of the serotonin transporter and associations with antidepressant response. Biol Psychiatry, 58:374–381, 2005.
26.
LettTA, WalterH, BrandlEJ: Pharmacogenetics and imaging-pharmacogenetics of antidepressant response: Towards translational strategies. CNS Drugs, 30:1169–1189, 2016.
27.
LinJY, JiangMY, KanZM, ChuY: Influence of 5-HTR2A genetic polymorphisms on the efficacy of antidepressants in the treatment of major depressive disorder: A meta-analysis. J Affect Disord, 168:430–438, 2014.
28.
LohoffFW, NarasimhanS, RickelsK: Interaction between polymorphisms in serotonin transporter (SLC6A4) and serotonin receptor 2A (HTR2A) genes predict treatment response to venlafaxine XR in generalized anxiety disorder. Pharmacogenomics J, 13:464–469, 2013.
29.
LuftMJ, LamyM, DelBelloMP, McNamaraRK, StrawnJR: Antidepressant-induced activation in children and adolescents: Risk, recognition and management. Curr Probl Pediatr Adolesc Health Care, 48:50–62, 2018.
30.
MarchJ, SilvaS, PetryckiS, CurryJ, WellsK, FairbankJ, BurnsB, DominoM, McNultyS, VitielloB, SevereJ, Treatment for Adolescents With Depression Study (TADS) Team: Fluoxetine, cognitive-behavioral therapy, and their combination for adolescents with depression: Treatment for Adolescents With Depression Study (TADS) randomized controlled trial. JAMA, 292:807–820, 2004.
31.
MasS, GassoP, AlvarezS, ParelladaE, BernardoM, LafuenteA: Intuitive pharmacogenetics: Spontaneous risperidone dosage is related to CYP2D6, CYP3A5 and ABCB1 genotypes. Pharmacogenomics J, 12:255–259, 2012.
32.
McMahonFJ, BuervenichS, CharneyD, LipskyR, RushAJ, WilsonAF, SorantAJM, PapanicolaouGJ, LajeG, FavaM, TrivediMH, WisniewskiSR, ManjiH: Variation in the gene encoding the serotonin 2A receptor is associated with outcome of antidepressant treatment. Am J Hum Genet, 78:804–814, 2006.
33.
NgCH, EastealS, TanS, SchweitzerI, HoBK, AzizS: Serotonin transporter polymorphisms and clinical response to sertraline across ethnicities. Prog Neuropsychopharmacol Biol Psychiatry, 30:953–957, 2006.
34.
NiitsuT, FabbriC, BentiniF, SerrettiA: Pharmacogenetics in major depression: A comprehensive meta-analysis. Prog Neuropsychopharmacol Biol Psychiatry, 45:183–194, 2013.
35.
ObachRS, CoxLM, TremaineLM: Sertraline is metabolized by multiple cytochrome P450 enzymes, monoamine oxidases, and glucuronyl transferases in human: An in vitro study. Drug Metab Dispos, 33:262–270, 2005.
36.
OdgerelZ, TalatiA, HamiltonSP, LevinsonDF, WeissmanMM: Genotyping serotonin transporter polymorphisms 5-HTTLPR and rs25531 in European- and African-American subjects from the National Institute of Mental Health's Collaborative Center for Genomic Studies. Transl Psychiatry, 3:e307, 2013.
37.
PaddockS, LajeG, CharneyD, RushAJ, WilsonAF, SorantAJ, LipskyR, WisniewskiSR, ManjiH, McMahonFJ: Association of GRIK4 with outcome of antidepressant treatment in the STAR*D cohort. Am J Psychiatry, 164:1181–1188, 2007.
38.
PerezV, SalavertA, EspadalerJ, TusonM, Saiz-RuizJ, Saez-NavarroC, BobesJ, Baca-GarciaE, VietaE, OlivaresJM, Rodriguez-JimenezR, VillagranJM, GasconJ, Canete-CrespilloJ, SoleM, SaizPA, IbanezA, de Diego-AdelinoJ, Ab-Gen CollaborativeGroup, MenchonJM: Efficacy of prospective pharmacogenetic testing in the treatment of major depressive disorder: Results of a randomized, double-blind clinical trial. BMC Psychiatry, 17:250, 2017.
39.
PerlisRH, FijalB, DhariaS, HeinlothAN, HoustonJP: Failure to replicate genetic associations with antidepressant treatment response in duloxetine-treated patients. Biol Psychiatry, 67:1110–1113, 2010.
40.
PetersEJ, SlagerSL, JenkinsGD, ReinaldaMS, GarriockHA, ShynSI, KraftJB, McGrathPJ, HamiltonSP: Resequencing of serotonin-related genes and association of tagging SNPs to citalopram response. Pharmacogenet Genomics, 19:1–10, 2009.
41.
PorcelliS, FabbriC, SerrettiA: Meta-analysis of serotonin transporter gene promoter polymorphism (5-HTTLPR) association with antidepressant efficacy. Eur Neuropsychopharmacol, 22:239–258, 2012.
42.
Probst-SchendzielorzK, VivianiR, StinglJC: Effect of cytochrome P450 polymorphism on the action and metabolism of selective serotonin reuptake inhibitors. Expert Opin Drug Metab Toxicol, 11:1219–1232, 2015.
43.
RamseyLB: Pharmacogenetic testing in children: What to test and how to use it. Curr Psychiatry, 17:30–36, 2018.
44.
RamseyLB, ProwsCA, ZhangK, SaldanaSN, SorterMT, PestianJP, WenstrupRJ, VinksAA, GlauserTA: Implementation of pharmacogenetics at Cincinnati Children's Hospital Medical Center: Lessons learned over 14 years of personalizing medicine. Clin Pharmacol Ther, 105:49–52, 2019.
45.
ReisM, AamoT, SpigsetO, AhlnerJ: Serum concentrations of antidepressant drugs in a naturalistic setting: Compilation based on a large therapeutic drug monitoring database. Ther Drug Monit, 31:42–56, 2009.
46.
ReisM, ChermaMD, CarlssonB, BengtssonF, Task Force for TDM of Escitalopram inSweden: Therapeutic drug monitoring of escitalopram in an outpatient setting. Ther Drug Monit, 29:758–766, 2007.
47.
RobbAS, CuevaJE, SpornJ, YangR, VanderburgDG: Sertraline treatment of children and adolescents with posttraumatic stress disorder: A double-blind, placebo-controlled trial. J Child Adolesc Psychopharmacol, 20:463–471, 2010.
48.
RochaA, CoelhoEB, SampaioSA, LanchoteVL: Omeprazole preferentially inhibits the metabolism of (+)-(S)-citalopram in healthy volunteers. Br J Clin Pharmacol, 70:43–51, 2010.
49.
RudbergI, HermannM, RefsumH, MoldenE: Serum concentrations of sertraline and N-desmethyl sertraline in relation to CYP2C19 genotype in psychiatric patients. Eur J Clin Pharmacol, 64:1181–1188, 2008.
50.
RynnMA, RiddleMA, YeungPP, KunzNR: Efficacy and safety of extended-release venlafaxine in the treatment of generalized anxiety disorder in children and adolescents: Two placebo-controlled trials. Am J Psychiatry, 164:290–300, 2007.
51.
RynnMA, SiquelandL, RickelsK: Placebo-controlled trial of sertraline in the treatment of children with generalized anxiety disorder. Am J Psychiatry, 158:2008–2014, 2001.
SakolskyD, NurmiE, BirmaherB, MarchJ, WalkupJ, PiacentiniJ, KendallP, AlbanoA, ComptonS, SherillJ, RynnM, GinsburgG, BadashovaK, McCrackenJ: Association of GRIK4 with treatment response in the Child/Adolescent Anxiety Multimodel Study (CAMS). New York, 10th Annual Meeting of the American Academcy of Child and Adolescent Psychiatry (AACAP), 2010 (poster).
54.
SerrettiA, ChiesaA, CrisafulliC, MassatI, LinotteS, CalatiR, KasperS, BailerU, LecrubierY, FinkM, AntonijevicI, ForrayC, SnyderL, BollenJ, ZoharJ, De RonchiD, SoueryD, MendlewiczJ: Failure to replicate influence of GRIK4 and GNB3 polymorphisms on treatment outcome in major depression. Neuropsychobiology, 65:70–75, 2012.
55.
StaekerJ, LeuchtS, LaikaB, SteimerW: Polymorphisms in serotonergic pathways influence the outcome of antidepressant therapy in psychiatric inpatients. Genet Test Mol Biomarkers, 18:20–31, 2014.
56.
StinglJC, BrockmollerJ, VivianiR: Genetic variability of drug-metabolizing enzymes: The dual impact on psychiatric therapy and regulation of brain function. Mol Psychiatry, 18:273–287, 2013.
57.
StrawnJR, MillsJA, CroarkinPE: Switching selective serotonin reuptake inhibitors in adolescents with selective serotonin reuptake inhibitor-resistant major depressive disorder: Balancing tolerability and efficacy. J Child Adolesc Psychopharmacol [Epub ahead of print]; DOI: 10.1089/cap.2018.0145, 2019a.
58.
StrawnJR, PoweleitEA, RamseyLB: CYP2C19-guided escitalopram and sertraline dosing in pediatric patients: A pharmacokinetic modeling study. J Child Adolesc Psychopharmacol [Epub ahead of print]; DOI: 10.1089/cap.2018.0160, 2019b.
59.
StrawnJR, WelgeJA, WehryAM, KeeshinB, RynnMA: Efficacy and tolerability of antidepressants in pediatric anxiety disorders: A systematic review and meta-analysis. Depress Anxiety, 32:149–157, 2015.
60.
UntereckerS, RiedererP, ProftF, MaloneyJ, DeckertJ, PfuhlmannB: Effects of gender and age on serum concentrations of antidepressants under naturalistic conditions. J Neural Transm (Vienna), 120:1237–1246, 2013.
61.
WalkupJT, AlbanoAM, PiacentiniJ, BirmaherB, ComptonSN, SherrillJT, GinsburgGS, RynnMA, McCrackenJ, WaslickB, IyengarS, MarchJS, KendallPC: Cognitive behavioral therapy, sertraline, or a combination in childhood anxiety. N Engl J Med, 359:2753–2766, 2008.
62.
WangJH, LiuZQ, WangW, ChenXP, ShuY, HeN, ZhouHH: Pharmacokinetics of sertraline in relation to genetic polymorphism of CYP2C19. Clin Pharmacol Ther, 70:42–47, 2001.
63.
WehryAM, RamseyL, DulembaSE, MossmanSA, StrawnJR: Pharmacogenomic testing in child and adolescent psychiatry: An evidence-based review. Curr Probl Pediatr Adolesc Health Care, 48:40–49, 2018.
64.
WinnerJG, CarhartJM, AltarCA, AllenJD, DechairoBM: A prospective, randomized, double-blind study assessing the clinical impact of integrated pharmacogenomic testing for major depressive disorder. Discov Med, 16:219–227, 2013.
65.
Yuce-ArtunN, BaskakB, Ozel-KizilET, OzdemirH, UckunZ, Devrimci-OzguvenH, SuzenHS: Influence of CYP2B6 and CYP2C19 polymorphisms on sertraline metabolism in major depression patients. Int J Clin Pharm, 38:388–394, 2016.
66.
ZeierZ, CarpenterLL, KalinNH, RodriguezCI, McDonaldWM, WidgeAS, NemeroffCB: Clinical implementation of pharmacogenetic decision support tools for antidepressant drug prescribing. Am J Psychiatry, 175:873–886, 2018.
67.
ZOLOFT. Zoloft (sertraline hydrochloride) [package insert]. New York, Pfizer, Inc., 2019. http://labeling.pfizer.com/ShowLabeling.aspx?id=517 Accessed April30, 2019
68.
ZubenkoGS, SommerBR, CohenBM: On the marketing and use of pharmacogenetic tests for psychiatric treatment. JAMA Psychiatry, 75:769–770, 2018.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
